Trial Profile
A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Milatuzumab-doxorubicin conjugate (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 19 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 07 May 2014 Trial status changed from suspended to recruiting as reported by ClinicalTrials.gov.